Successful treatment of resistant visceral leishmaniasis with liposomal amphotericin B

Gokhale, Prafulla C.; Kshirsagar, Nilima A; Khan, Momin; Pandya, Sunil K; Meisheri, Yogini V.; Thakur, C.P.; Choudhary, Cuckoo

doi:10.1016/0035-9203(94)90309-3

Cited by 17 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Substantial progress will only come about, however, if continued vigorous research efforts to develop more therapeutic and less toxic drug molecules are paralleled by the aggressive pursuit of more effective mechanisms for delivering those drugs to brain targets. [19] Jain et al . developed dopamine hydrochloride bearing positively charged small liposomes by sonicating multilamellar vesicles and studied their physical attributes and drug leakage and release pattern.…”

Section: Liposomal and Targeted Drug Delivery Systemmentioning

confidence: 99%

Drug delivery systems: An updated review

Tiwari

Sriwastawa

et al. 2012

Int J Pharma Investig

1,299

642

View full text Add to dashboard Cite

Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals. For the treatment of human diseases, nasal and pulmonary routes of drug delivery are gaining increasing importance. These routes provide promising alternatives to parenteral drug delivery particularly for peptide and protein therapeutics. For this purpose, several drug delivery systems have been formulated and are being investigated for nasal and pulmonary delivery. These include liposomes, proliposomes, microspheres, gels, prodrugs, cyclodextrins, among others. Nanoparticles composed of biodegradable polymers show assurance in fulfilling the stringent requirements placed on these delivery systems, such as ability to be transferred into an aerosol, stability against forces generated during aerosolization, biocompatibility, targeting of specific sites or cell populations in the lung, release of the drug in a predetermined manner, and degradation within an acceptable period of time.

show abstract

Section: Liposomal and Targeted Drug Delivery Systemmentioning

confidence: 99%

Drug delivery systems: An updated review

Tiwari

Sriwastawa

et al. 2012

Int J Pharma Investig

1,299

642

View full text Add to dashboard Cite

show abstract

“…Other drugs used in visceral leishmaniasis are amphotericin B and liposomal amphotericin B [11,14,18,27,36], allopurinol [3,6], paromomycin [52,54], dapsone, rifampicin [15], and interferon gamma [21,37,44,45,46]. The oral therapies (allopurinol, dapsone, rifampicin) have no proven value in the leishmaniases.…”

Section: Introductionmentioning

confidence: 99%

Miltefosine (Impavido): the first oral treatment against leishmaniasis

Sindermann

Croft

Engel

et al. 2003

Med Microbiol Immunol

View full text Add to dashboard Cite

Miltefosine is a novel antileishmanial drug that has significant selectivity in both in vitro and in vivo models. Clinical efficacy was demonstrated for the treatment of visceral leishmaniasis with the advantage of oral administration over the currently recommended antileishmanial drugs that require parenteral administration. Miltefosine produces high cure rates also in patients resistant to the standard antimonial therapy.

show abstract

“…VL manifests itself in these cells, and so, serendipitously, drugs can be targeted to the site of an infection by Leishmania donovani parasites. Several amphotericin B-lipid formulations have now been tested against both experimental (15,28,37) and clinical (10,11,13,34) infections caused by L. donovani, of which AmBisome (NeXStar Inc., San Dimas, Calif.), a unilamellar liposome, has been the most widely used (6,7,33). In experimental VL models, AmBisome accumulates in the liver, reaching therapeutic levels more quickly than conventional antimonial drugs (15).…”

mentioning

confidence: 99%

Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis

Yardley

Croft

1997

Antimicrob Agents Chemother

123

View full text Add to dashboard Cite

The polyene antibiotic amphotericin B is currently a second-line treatment for visceral leishmaniasis (VL) and mucocutaneous leishmaniasis. Lipid-amphotericin B formulations with lower toxicity than the parent drug that were developed for the treatment of systemic mycoses have proved to be an effective treatment for VL, especially AmBisome, a small unilamellar negatively charged liposome. In vitro, free amphotericin B was three to six times more active than the liposomal formulation AmBisome against both Leishmania major promastigotes in culture and amastigotes in murine macrophages. In a BALB/c L. major model of cutaneous infection, liposomal amphotericin B administered once a day on six alternate days by the intravenous route produced a dose-response effect between 6.25 and 50 mg/kg. Liposomal amphotericin B administered subcutaneously close to a lesion had no significant activity. Free drug was ineffective at nontoxic doses. The results suggest that liposomal amphotericin B may be useful in the treatment of cutaneous leishmaniasis.

show abstract

Successful treatment of resistant visceral leishmaniasis with liposomal amphotericin B

Cited by 17 publications

References 5 publications

Drug delivery systems: An updated review

Drug delivery systems: An updated review

Miltefosine (Impavido): the first oral treatment against leishmaniasis

Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis

Contact Info

Product

Resources

About